AI Insight
The SINGLE-AF clinical trial found that oral anticoagulant therapy reduced the risk of adverse clinical events in patients with atrial fibrillation who have intermediate stroke risk, compared to those receiving no anticoagulation. The results were presented at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine. This expands evidence for anticoagulation use beyond high-risk patients to include an intermediate-risk population.
Why it matters
This finding may change clinical practice guidelines by extending anticoagulation therapy recommendations to a broader population of atrial fibrillation patients previously considered at borderline risk for treatment. It could help prevent strokes and other adverse events in millions of patients worldwide who fall into the intermediate-risk category.
Understand the Science
Oral anticoagulant therapy lowered the risk of adverse clinical events compared with no anticoagulation in patients with atrial fibrillation at intermediate stroke risk, according to results from the SINGLE-AF trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.